The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares the updates in chronic lymphocytic leukemia (CLL) from ASH 2025 that she is most excited about. She highlights the CLL17 trial (NCT04608318), which provides insights into the effectiveness of time-limited treatment. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, of course I’m biased, but of course I’m most excited about the plenary session on the abstract from our study group in cooperation with other study groups, the CLL17 trial. And I think it’s really important to see the data right now with respect to the question of time-limited versus continuous treatment. So the follow-up with three years is for CLL today in frontline still relatively short, but the data confirm that really time-limited treatment is as effective as continuous treatment and therefore patients can go off treatment and hopefully have less side effects and also in the end these treatments will be less expensive...
Yeah, of course I’m biased, but of course I’m most excited about the plenary session on the abstract from our study group in cooperation with other study groups, the CLL17 trial. And I think it’s really important to see the data right now with respect to the question of time-limited versus continuous treatment. So the follow-up with three years is for CLL today in frontline still relatively short, but the data confirm that really time-limited treatment is as effective as continuous treatment and therefore patients can go off treatment and hopefully have less side effects and also in the end these treatments will be less expensive.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
